>
Switch to:

Biohaven Pharmaceutical Holding Co Inventory-to-Revenue

: 0.66 (As of Jun. 2021)
View and export this data going back to 2017. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biohaven Pharmaceutical Holding Co's Total Inventories for the quarter that ended in Jun. 2021 was $61.2 Mil. Biohaven Pharmaceutical Holding Co's Revenue for the three months ended in Jun. 2021 was $92.9 Mil. Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue for the quarter that ended in Jun. 2021 was 0.66.

Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue for the quarter that ended in Jun. 2021 declined from Mar. 2021 (1.12) to Mar. 2021 (0.66)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biohaven Pharmaceutical Holding Co's Days Inventory for the three months ended in Jun. 2021 was 322.04.

Total Inventories can be measured by Days Sales of Inventory (DSI). Biohaven Pharmaceutical Holding Co's days sales of inventory (DSI) for the three months ended in Jun. 2021 was 60.09.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biohaven Pharmaceutical Holding Co's Inventory Turnover for the quarter that ended in Jun. 2021 was 0.28.


Biohaven Pharmaceutical Holding Co Inventory-to-Revenue Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Inventory-to-Revenue
Premium Member Only - - - - 0.62

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.82 0.85 1.12 0.66

Competitive Comparison

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Pharmaceutical Holding Co Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue falls into.



Biohaven Pharmaceutical Holding Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Inventory-to-Revenue (A: Dec. 2020 )
=Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2019 ) + Total Inventories (A: Dec. 2020 )) / count ) / Revenue (A: Dec. 2020 )
=( (0 + 39.563) / 1 ) / 63.627
=39.563 / 63.627
=0.62

Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue for the quarter that ended in Jun. 2021 is calculated as

Inventory-to-Revenue (Q: Jun. 2021 )
=Total Inventories / Revenue
=( (Total Inventories (Q: Mar. 2021 ) + Total Inventories (Q: Jun. 2021 )) / count ) / Revenue (Q: Jun. 2021 )
=( (58.329 + 64.058) / 2 ) / 92.933
=61.1935 / 92.933
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biohaven Pharmaceutical Holding Co's Days Inventory for the three months ended in Jun. 2021 is calculated as:

Days Inventory=Total Inventories (Q: Jun. 2021 )/Cost of Goods Sold (Q: Jun. 2021 )*Days in Period
=61.1935/17.339*365 / 4
=322.04

2. Total Inventories can be measured by Days Sales of Inventory (DSI).

Biohaven Pharmaceutical Holding Co's Days Sales of Inventory for the three months ended in Jun. 2021 is

Days Sales of Inventory (DSI)=Total Inventories (Q: Jun. 2021 )/Revenue (Q: Jun. 2021 )*Days in Period
=61.1935/92.933*365 / 4
=60.09

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biohaven Pharmaceutical Holding Co's Inventory Turnover for the quarter that ended in Jun. 2021 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2021 ) / Total Inventories (Q: Jun. 2021 )
=17.339 / 61.1935
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co Business Description

Biohaven Pharmaceutical Holding Co logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Bailey Gregory director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Gentile Kimberly officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Childs John W director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Berman Robert officer: Special Projects & Med Ovrsght C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Doogan Declan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Stock Elyse officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
Engelhart James officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Tilton John officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Hugin Robert J director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Heffernan Michael Thomas director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Gregory Julia P director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Aguiar Eric director 888 7TH AVENUE 12TH FLOOR NEW YORK NY 10106
Coric Vlad director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC. 125 SPRING STREET LEXINGTON MA 02421
Conway Charles officer: Chief Scientific Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510

Biohaven Pharmaceutical Holding Co Headlines

Other Sources

Company News for Jul 8, 2021

By Zacks 2021-07-08

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)